Results 131 to 140 of about 1,419,720 (263)

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source

Therapeutic interventions for chronic central serous chorioretinopathy: a comprehensive assessment of systematic reviews

International Journal of Retina and Vitreous
Background A variety of different treatments have been proposed to effectively treat chronic central serous chorioretinopathy but there remains uncertainty regarding the efficacy of a number of treatment options.
Henok Getahun, Rajendra S. Apte
doaj   +1 more source

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease

Frontiers in Pharmacology
Every year millions die prematurely of complications related to chronic kidney disease (CKD). Main causes of death are connected with cardiovascular (CV) complications.
Mai Rosenberg, Alexei Y. Bagrov
doaj   +1 more source

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton, Myrte Schoenmakers, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F. C. van Rossum   +4 more
wiley   +1 more source

Blood pressure response to mineralocorticoid receptor antagonists or aldosterone synthase inhibitors according to baseline renin levels

International audiencePlasma renin is a surrogate marker of sodium retention in hypertension, and its levels are suppressed in conditions of heightened aldosterone production.
Angélico-Gonçalves, António, Leite-Moreira, Adelino, Leite, Ana Rita, Neves, João Sérgio, Ferreira, João Pedro   +4 more
core   +1 more source

Multisystem developmental abnormalities and insulin resistance in ADTKD‐HNF1B with the p.E105K variant: A clinical conundrum

Diabetic Medicine, EarlyView.
Abstract Aims HNF1B variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD‐HNF1B), but the phenotypic spectrum of variants of uncertain significance (VUS) remains incompletely defined. We aimed to characterise the multisystem phenotype associated with the HNF1B p.E105K variant and to examine the mechanism underlying insulin ...
YunZe Wang, KangChun Xu, PengFei Liu, Bin Wang, Yan Yang, ShanZhai Wei   +5 more
wiley   +1 more source

Mineralocorticoid receptor antagonists for primary aldosteronism—appropriate or not?

European Journal of Endocrinology, 2023
Oskar Ragnarsson, Per Dahlqvist, Andreas Muth, Jan Calissendorff, Tommy Olsson   +4 more
openaire   +3 more sources

Early sodium‐glucose co‐transporter 2 inhibitor initiation is associated with improved cardiovascular outcomes in type 2 diabetes and acute coronary syndrome

Diabetic Medicine, EarlyView.
Abstract Aims Sodium‐glucose co‐transporter 2 inhibitors have demonstrated cardiovascular benefits in individuals with type 2 diabetes mellitus, but the optimal timing of initiation in those with acute coronary syndrome is not known. This study aims to assess if early therapy at discharge is superior to delayed or no therapy in reduction in major ...
Muhammad Usman Shah, Joanna Kate Ward, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee   +7 more
wiley   +1 more source

Kidney Outcomes With GLP‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel   +5 more
wiley   +1 more source

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman, Jan Basile, Robert Busch, David M. Charytan, Kenneth W. Mahaffey, Sherif Mehanna, Søren Rasmussen, Peter Rossing, Caroline Swift, Katherine R. Tuttle, Richard Pratley   +10 more
wiley   +1 more source